Latest News and Press Releases

NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today...

Gerard Michel Brings the Experience Needed to Lead Delcath as it Transitions from a Development to Commercial Stage CompanyJohn Purpura Appointed Chief Operating Officer with Operational,...

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers,...

NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today...

NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today...

NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today...

Appoints John Purpura as interim Chief Executive Officer.Reiterates intention to announce top-line data from Phase 3 FOCUS trial by year-endAccelerates shift to commercialization planning NEW YORK,...

Highlights include $22 million public offering, uplisting to Nasdaq, Pivotal Registration Trial enrollment completed, and Pivotal Registration Topline Data Expected in 2020 NEW YORK, May 15, 2020 ...

NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...